<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131443</url>
  </required_header>
  <id_info>
    <org_study_id>CAPSS 271</org_study_id>
    <nct_id>NCT00131443</nct_id>
  </id_info>
  <brief_title>Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine</brief_title>
  <official_title>A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monarch Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Neurologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Monarch Medical Research</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effectiveness and safety of topiramate in the&#xD;
      prevention of basilar and hemiplegic migraine in children and adolescents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the efficacy and safety of topiramate in the&#xD;
      prophylaxis of basilar migraine and hemiplegic migraine in children and adolescents, by&#xD;
      comparing two doses, 25 and 100 mg/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy outcome will be the reduction in average monthly migraine-days over the entire double-blind phase relative to the prospective baseline period</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in frequency, severity and duration of basilar or hemiplegic aura symptoms</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in migraine pain severity and duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in migraine episode and headache episode frequency</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in total headache days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders (i.e., the proportion of subjects who experience a â‰¥ 50% reduction in migraine-days and migraine episodes)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative reduction in frequency of migraine days and migraine episodes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the use of acute/abortive medications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in migraine-associated symptoms</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Basilar Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must meet International Headache Society (IHS) classification of pediatric migraine&#xD;
             with aura: familial hemiplegic migraine (International Classification of Headache&#xD;
             Disorders [ICHD] 1.2.4), sporadic hemiplegic migraine (ICHD 1.2.5) or basilar-type&#xD;
             migraine (ICHD 1.2.6).&#xD;
&#xD;
          -  Average of 4 migraine-days/month during the 3 months prior to screening.&#xD;
&#xD;
          -  4 migraine-days during prospective baseline period.&#xD;
&#xD;
          -  At least one of the subject's migraines during the previous 3 months must have been&#xD;
             accompanied by their characteristic basilar-type or hemiplegic neurologic symptoms of&#xD;
             moderate to severe degree.&#xD;
&#xD;
          -  6-18 years of age.&#xD;
&#xD;
          -  Weigh more than 25 kg.&#xD;
&#xD;
          -  If female, subjects must:&#xD;
&#xD;
               1. be premenarchal or otherwise incapable of pregnancy, or&#xD;
&#xD;
               2. have practiced one of the following methods of contraception for at least one&#xD;
                  month prior to study entry: hormonal contraceptives, spermicide and barrier,&#xD;
                  intrauterine device, spousal/partner sterility, or&#xD;
&#xD;
               3. be practicing abstinence and agree to continue abstinence or to use an acceptable&#xD;
                  method of contraception (as listed above) should sexual activity commence.&#xD;
&#xD;
        If (b) or (c), the subject must have a negative urine pregnancy test within one week of&#xD;
        study entry.&#xD;
&#xD;
          -  Able to take oral medication in tablet form&#xD;
&#xD;
          -  Willing and able to:&#xD;
&#xD;
               1. read and comprehend written instructions,&#xD;
&#xD;
               2. complete the assessment forms,&#xD;
&#xD;
               3. return for regular visits, and d) adhere to medication regimens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously failed topiramate therapy for migraine prophylaxis or those who&#xD;
             discontinued topiramate due to adverse events.&#xD;
&#xD;
          -  Have taken topiramate within 14 days prior to the start of the prospective baseline&#xD;
             period.&#xD;
&#xD;
          -  Have 15 or more headache-days during the prospective baseline period.&#xD;
&#xD;
          -  Have cluster headaches or chronic migraine.&#xD;
&#xD;
          -  Have migraine aura without headache exclusively.&#xD;
&#xD;
          -  Currently have a more painful condition than their migraine pain.&#xD;
&#xD;
          -  Have taken any medications for migraine prophylaxis, within 2 weeks of the start of&#xD;
             the prospective baseline period.&#xD;
&#xD;
          -  Progressive neurological disorders or a structural disorder of the brain&#xD;
&#xD;
          -  Overuse analgesic or migraine-specific agents for abortive treatment of migraine:&#xD;
&#xD;
               -  &gt;10 treatment days/month of ergot-containing medication, triptans, or opioids;&#xD;
&#xD;
               -  &gt;15 treatment days/month with simple analgesics (including NSAIDs)&#xD;
&#xD;
          -  Require any injections of corticosteroids or local anesthetics within 60 days of visit&#xD;
             1 or botulinum toxin within 120 days prior to Visit 1.&#xD;
&#xD;
          -  Have previously failed more than 2 adequate trials of an established prophylactic&#xD;
             anti-migraine regimen.&#xD;
&#xD;
          -  Subjects starting non-pharmacologic prophylactic approaches within 1 month prior to&#xD;
             Visit 1. Non-pharmacologic prophylactic approaches started at least 1 month prior to&#xD;
             Visit 1 should be continued throughout the study.&#xD;
&#xD;
          -  Have taken carbonic anhydrase inhibitors or triamterene within 1 month prior to Visit&#xD;
             1.&#xD;
&#xD;
          -  History of nephrolithiasis.&#xD;
&#xD;
          -  Require continuing treatment with anticonvulsant therapy for a non-migraine condition.&#xD;
&#xD;
          -  Significant major psychiatric disorder (e.g., major depression) or subjects receiving&#xD;
             anti-psychotic medication.&#xD;
&#xD;
          -  History of attempted suicide or suicidal tendencies.&#xD;
&#xD;
          -  History of substance abuse.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Clinically unstable neurological, cardiovascular, gastrointestinal, musculoskeletal,&#xD;
             pulmonary or other disease.&#xD;
&#xD;
          -  Active liver disease.&#xD;
&#xD;
          -  AST and/or ALT levels greater than 2 times the upper limit of normal range.&#xD;
&#xD;
          -  Received an investigational drug or used an investigational device within 30 days of&#xD;
             study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald W Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monarch Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monarch Medical Research - Child and Adolescent Neurology</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <last_update_submitted>November 9, 2012</last_update_submitted>
  <last_update_submitted_qc>November 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 12, 2012</last_update_posted>
  <keyword>Basilar/Hemiplegic Migraine</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

